10-K: Monogram Orthopaedics Details Capital Structure and Anti-Takeover Measures in 10-K Filing

Monogram Orthopaedics' 10-K filing outlines its capital structure, including common and preferred stock details, and anti-takeover provisions.

Summary

• Monogram Orthopaedics' authorized capital stock consists of 90,000,000 shares of Common Stock and 60,000,000 shares of Preferred Stock, with a par value of $0.001 per share.
• All outstanding shares of Preferred Stock automatically converted into Common Stock upon the declaration of effectiveness of a Form 8-A on May 17, 2023.
• As of August 9, 2023, the company's outstanding capital stock solely consists of 29,253,251 shares of Common Stock.
• The company's certificate of incorporation includes a forum selection provision requiring claims against the company to be brought in the Delaware Court of Chancery.
• The company has authorized but unissued shares of Preferred and Common Stock, which the Board of Directors may use to discourage takeovers.
• Special meetings of stockholders can only be called by the Board, the President, or stockholders holding at least 67% of the outstanding shares.
• Each share of Common Stock is entitled to one vote, and holders are entitled to dividends as declared by the Board.
• In the event of liquidation, Common Stock holders share ratably in net assets after debts and liabilities are paid.
• The CEO, Benjamin Sexson, has pre-emptive rights to maintain his equity position in the event of additional stock issuances.
• ZB Capital Partners has warrants to acquire $1,000,000 worth of Preferred Stock, exercisable at $3.65 per share, expiring in February 2024.
• Pro-Dex has warrants to acquire up to 5% of the outstanding stock, exercisable at $1,250,000, expiring on December 20, 2025, or upon an IPO or liquidation event.
• The company is in discussions with Pro-Dex regarding the exercise of its warrants in exchange for new terms to their development and supply agreement.

Sentiment

Score: 6

Explanation: The document is neutral in tone, providing factual information about the company's capital structure and governance. While there are some potential negatives, such as anti-takeover provisions, they are common in corporate filings. The document does not express any strong positive or negative sentiment.

Positives

• The company has a clear capital structure with a defined number of authorized shares.
• The conversion of preferred stock simplifies the capital structure.
• The forum selection clause may reduce litigation costs and management time.
• The company has the ability to issue additional shares for strategic purposes.
• The CEO's pre-emptive rights protect his equity position.

Negatives

• The forum selection provision may limit investors' ability to bring claims in favorable jurisdictions.
• Anti-takeover provisions could discourage potential acquisitions.
• The high threshold for stockholders to call a special meeting may limit their influence.
• The company has never declared or paid cash dividends and does not anticipate doing so in the foreseeable future.
• The potential exercise of warrants by ZB Capital Partners and Pro-Dex could dilute existing shareholders.

Risks

• The forum selection provision may discourage lawsuits against the company.
• Anti-takeover provisions could deter potential acquirers and limit shareholder value.
• The high threshold for calling special meetings may limit shareholder influence.
• The potential exercise of warrants could dilute existing shareholders.
• Ongoing discussions with Pro-Dex regarding warrant exercise and supply agreement terms could lead to unfavorable outcomes.

Future Outlook

The company does not anticipate paying any cash dividends in the foreseeable future and may use authorized but unissued shares for strategic purposes.

Management Comments

• The company has adopted the forum selection provision to limit the time and expense incurred by its management to challenge any such claims.
• The company believes that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us.
• Mr. Sexson does not intend to exercise his pre-emptive right in this offering.

Industry Context

The document provides insight into the capital structure and governance of a medical device company, which is typical for companies in this sector. The anti-takeover provisions are common among companies seeking to protect themselves from hostile acquisitions.

Comparison to Industry Standards

• The use of a forum selection clause is becoming increasingly common among Delaware corporations to manage litigation costs and ensure predictability.
• The authorization of a large number of unissued shares is a standard practice for companies to maintain flexibility for future financing and strategic opportunities.
• The anti-takeover provisions, such as the classified board and limitations on calling special meetings, are similar to those used by other public companies to protect against hostile takeovers.
• The warrant agreements with ZB Capital Partners and Pro-Dex are typical financing arrangements for early-stage companies, providing capital in exchange for potential equity dilution.

Corporate Governance

Related Party Transactions

• ZB Capital Partners has warrants to acquire $1,000,000 worth of shares of the Companys Preferred Stock.
• Pro-Dex has warrants to acquire up to 5% of the outstanding Common Stock and Preferred Stock of the Company.
• Richard L. Van Kirk, the Chief Executive Officer of Pro-Dex, Inc., is a Director of Monogram.

Stakeholder Impact

• Shareholders may be impacted by potential dilution from the exercise of warrants.
• Shareholders may have limited influence due to the high threshold for calling special meetings.
• Potential acquirers may be discouraged by the anti-takeover provisions.
• Management may have more control due to the forum selection clause and anti-takeover provisions.

Next Steps

• The company will continue discussions with Pro-Dex regarding the exercise of its warrants and the development and supply agreement.
• The company may issue additional shares of Preferred or Common Stock in the future.
• ZB Capital Partners may exercise its warrants before their expiration in February 2024.
• Pro-Dex may exercise its warrants before their expiration in December 2025 or upon an IPO or liquidation event.

Key Dates

Keywords

capital stock, common stock, preferred stock, warrants, anti-takeover, forum selection, pre-emptive rights, ZB Capital Partners, Pro-Dex, Delaware Court of Chancery